Book a Meeting

Anti-IL17A Antibody, On-Target (CAT#: AES-0622-ZP809) Datasheet

Target
IL17A
Description
Anti-IL17A antibody takes advantage of the enrichment of some small molecules such as ATP in the tumor microenvironment, and activates the antibody by using the small molecule as a medium, so that the antibody is specifically activated only in the tumor.
Applications
"On-target" tumor antigen binding
Technology
ATP-mediated antibody engineering technology

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced IL17A antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
Interleukin 17A
Background
Secukinumab; Cosentyx; 875356-43-7; AIN457; DB09029IL17A; interleukin 17A; CTLA8; IL17; interleukin 17 (cytotoxic T lymphocyte associated serine esterase 8); interleukin-17A; cytotoxic T lymphocyte associated protein 8; IL 17; IL 17A; CTLA-8;
Antibody Clone
AES-0622-ZP809
Description
Anti-IL17A antibody takes advantage of the enrichment of some small molecules such as ATP in the tumor microenvironment, and activates the antibody by using the small molecule as a medium, so that the antibody is specifically activated only in the tumor.

Related Products

Non-fucosylated Anti-Human IL17A (Vunakizumab) Therapeutic Antibody (CAT#: BioBet-290ZP)
Anti-IL17A Antibody, Half-Life Extended (CAT#: AES-0622-ZP1137)
Anti-IL17A Antibody, Recycling (CAT#: AES-0622-ZP153)
Highly Galactosylated Anti-IL17A (Bimekizumab) Antibody (CAT#: BioBet-GA-291ZP)
Non-Fucosylated Anti-Human IL17A (ANB004) Therapeutic Antibody (CAT#: BioBet-1055ZP)
Highly Galactosylated Anti-IL17A (Vunakizumab) Antibody (CAT#: BioBet-GA-290ZP)
Anti-IL17A Antibody, FcγRIIB Binding Enhanced (CAT#: AES-0622-ZP481)
Anti-IL17A Antibody, Highly Galactosylated (CAT#: BioBet-GA-289ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.